An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-07-01
Serie:	EBioMedicine
Soggetti:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!